The company is focused on the development of cancer treatment products for veterinary and human applications based on an innovative noninvasive ablation technology The company is focused on the development of cancer treatment products for human, veterinary and research applications based on an innovative noninvasive ablation technology. Our technology is a platform technology that may be used as a
n alternative to surgery for the treatment of early-stage breast, head & neck, skin and lung cancers. It may also be used for pain relief in palliative care treatments. The proven technology can locally ablate and destroy cancer tumors, precisely and effectively, without causing any damage to the surrounding healthy tissues. It is based on using specialized noninvasive electromagnetic applicators that are placed around the region of interest along with FDA/CE approved nanoparticles that are placed inside the tumor. The device is controlled through the company’s own developed algorithms that optimize the ablation process while precisely tracking temperature and measuring the administered treatment dose. The technology has been tested on mice with excellent results and is currently being tested on dogs for the veterinary market. The company is also planning its first-in-human studies. The company is currently seeking VC funding and strategic partnerships with large medical device corporations and hospital consortiums. The company is also accepting pre-orders of devices for R&D and veterinary use. For private investors, for a limited time, you can invest in SynergyMed through our equity-based crowdfunding campaign https://wefunder.com/synergymed/
